Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial
Background: The aim of this study was to evaluate the efficacy and safety of gemcitabine plus nab-paclitaxel (GnP) as second-line chemotherapy following first-line FOLFIRINOX treatment failure in advanced pancreatic cancer. Methods: This was a multicenter, single-arm, open-label, phase 2 trial done...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
SAGE Publishing
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/7cf00d3ed7144f5ab1e9bea7d971835c |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|